backgroundchron
lymphocyt
leukemia
cll
patient
high
risk
acut
respiratori
ill
ari
objectiveevalu
safetyefficaci
proprietari
extract
panax
quinequefoliu
afexa
life
scienc
reduc
ari
methodsdoubleblind
placebocontrol
random
subject
earlystag
untreat
cll
januarymarch
resultsari
day
common
occur
day
studi
period
signific
differ
two
priori
primari
endpoint
ari
day
vs
placebo
sever
ari
day
vs
placebo
howev
percent
vs
placebo
recipi
experienc
least
one
ari
diff
ci
intens
ari
occur
vs
placebo
recipi
diff
ci
symptomspecif
evalu
show
reduc
moderatesever
sore
throat
p
lower
rate
grade
toxic
p
recipi
greater
seroconvers
increas
antibodi
titer
vs
common
viral
pathogen
document
recipi
vs
p
limitationsserolog
evalu
antibodi
titer
tie
specif
ill
evalu
entir
studi
period
well
reduc
number
ari
day
antibiot
use
howev
trend
toward
reduc
rate
moderatesever
ari
significantli
less
sore
throat
suggest
increas
rate
seroconvers
like
reflect
antibodi
respons
chronic
lymphocyt
leukemia
cll
common
adult
leukemia
account
nearli
onethird
leukemia
almost
case
cll
occur
adult
median
age
diagnosi
median
surviv
year
initi
treatment
earlystag
patient
often
requir
treatment
mani
year
diagnosi
underli
cll
treatment
result
immun
compromis
particularli
poor
antibodi
respons
infect
common
common
infect
cll
patient
acut
respiratori
infect
ari
mani
ari
viral
antibiot
frequent
prescrib
sinc
difficult
differenti
viral
bacteri
infect
rate
major
infect
ie
infect
sever
enough
requir
hospit
treatment
parenter
antibiot
per
patient
per
month
patient
treat
chlorambucil
fludarabin
combin
respect
untreat
cll
patient
prone
infect
similar
age
patient
nonmalign
comorbid
ie
myocardi
infarct
base
data
publish
year
ago
recent
data
data
includ
patient
mix
cll
stage
sinc
vast
major
cll
patient
age
like
immun
senesc
wane
immun
advanc
age
also
risk
factor
infect
recent
studi
suggest
mean
number
ari
day
respiratori
ill
winter
season
within
age
group
strategi
prevent
infect
problemat
cll
inadequ
antibodi
respons
render
vaccin
less
effect
infus
intraven
immunoglobulin
ivig
use
subject
low
serum
immunoglobulin
g
igg
mgdl
howev
ivig
use
controversi
due
suppli
issu
lack
consensu
frequenc
administr
dose
question
costeffect
expens
therapi
approxim
life
year
gain
prophylact
antibiot
much
less
expens
strategi
like
enhanc
antimicrobi
resist
poor
complianc
prophylaxi
common
viral
pathogen
avail
thu
press
need
effect
lowcost
intervent
enhanc
immun
reduc
infect
risk
limit
antibiot
use
cll
patient
patent
mixtur
polysaccharid
isol
panax
quinquefoliu
afexa
life
scienc
edmonton
canada
investig
immunomodulatori
compound
accumul
data
mechan
action
indic
innat
immun
modul
act
tolllik
receptor
surfac
cell
activ
lead
increas
number
function
cell
within
innat
adapt
immun
system
reduc
incid
ari
adult
importantli
three
studi
perform
older
adult
popul
affect
cll
one
studi
healthi
communitydwel
senior
show
reduc
number
day
respiratori
ill
symptom
anoth
studi
conduct
longterm
care
nurs
home
resid
main
endpoint
laboratoryconfirm
symptomat
influenza
placebo
recipi
confirm
influenza
respiratori
syncyti
viru
rsv
ill
vs
recipi
p
third
studi
conduct
communitydwel
senior
incid
respiratori
ill
decreas
onethird
recipi
p
addit
older
age
import
parallel
subject
publish
studi
cll
patient
subject
two
studi
highli
immun
receiv
influenza
vaccin
within
two
year
thu
case
influenza
repres
vaccin
failur
also
characterist
longterm
care
resid
older
age
multipl
comorbid
impair
immun
includ
ineffect
vaccin
respons
close
resembl
popul
immun
milieu
cll
patient
base
parallel
need
effect
prevent
measur
ari
cll
patient
perform
random
doubleblind
placebocontrol
trial
reduc
ari
need
antibiot
treatment
cll
patient
subject
enrol
novemb
decemb
site
affili
commun
clinic
oncolog
program
ccop
research
base
wake
forest
univers
comprehens
cancer
center
nci
cancer
trial
studi
unit
ctsu
inclus
criteria
age
phenotyp
evid
cll
flow
cytometri
bone
marrow
ecog
zubrod
perform
statu
life
expect
month
abl
provid
inform
consent
exclus
criteria
hiv
cirrhosi
autoimmun
diseas
eg
multipl
sclerosi
malign
cll
nonmelanoma
skin
cancer
carcinoma
situ
cervix
allow
creatinin
clearanc
mlmin
sgot
ast
sgpt
alt
uln
total
bilirubin
uln
current
prior
treatment
fludarabin
alemtuzumab
rituximab
ivig
hematopoiet
stem
cell
transplant
current
recent
win
month
therapi
chlorambucil
current
treatment
corticosteroid
equival
mgday
prednison
use
antibiot
prophylaxi
trimethoprimsulfamethoxazol
tmpsmx
current
use
warfarin
allergi
ginseng
product
current
use
herbal
product
unwil
discontinu
subject
stratifi
use
prophylact
tmpsmx
yesno
serum
igg
mg
dl
vs
mgdl
influenza
vaccin
statu
enrol
year
yesno
random
receiv
mg
twice
daili
match
placebo
microcrystallin
cellulos
oral
treatment
continu
time
enrol
april
allow
consist
period
time
subject
protocol
januari
period
encompass
time
maximum
respiratori
tract
infect
influenza
risk
januaryapril
regardless
geographi
us
main
outcom
measur
ari
day
fix
threemonth
period
januari
subject
took
addit
month
ensur
secondari
endpoint
met
encompass
potenti
late
influenza
season
treatment
period
subject
seen
enrol
week
week
endofstudi
followup
phone
call
perform
week
later
assess
advers
event
subject
kept
daili
symptom
diari
determin
number
ari
day
studi
personnel
instruct
subject
enrol
regard
item
diari
symptom
specif
queri
daili
includ
cough
sore
throat
nasalsinu
congest
runni
nose
feverish
chillssweat
myalgia
muscl
ach
fatigu
headach
poor
endur
increas
short
breath
symptom
rate
scale
sever
felt
feverish
subject
ask
take
temperatur
oral
home
thermomet
subject
also
indic
whether
symptom
limit
particip
usual
activ
ari
day
defin
day
subject
experienc
respiratori
symptom
cough
sore
throat
nasal
sinu
congest
runni
nose
system
symptom
feverish
chillssweat
myalgia
fatigu
headach
poor
endur
increas
short
breath
use
rate
scale
symptom
allow
first
valid
instrument
cll
patient
commonli
use
uri
scale
modifi
jackson
criteria
cold
later
refin
gwaltney
sever
ari
day
defin
ari
day
one
follow
fever
oral
temperatur
limit
particip
usual
activ
antibiot
use
day
aud
defin
day
system
oralparenter
antibiot
given
multipl
time
reason
exclud
prophylact
tmpsmx
subject
record
inform
antibiot
use
form
entri
confirm
studi
personnel
visit
toxic
evalu
standard
common
toxic
criteria
nci
version
untoward
advers
event
report
irb
cccwfu
clinic
research
oversight
committe
review
enzym
immunoassay
eia
perform
detect
virusspecif
serum
igg
nine
respiratori
virus
influenza
b
rsv
parainfluenza
piv
viru
serotyp
human
metapneumoviru
hmpv
coronaviru
per
publish
method
briefli
antigen
produc
viral
infect
whole
cell
lysat
virus
except
rsv
purifi
viral
surfac
glycoprotein
use
antigen
rsv
eia
accord
publish
method
pair
serum
sampl
screen
singl
dilut
show
increas
optic
densiti
read
baselin
endofstudi
specimen
test
full
dilut
determin
antibodi
titer
serial
twofold
dilut
sampl
test
duplic
seroconvers
defin
rise
antibodi
baselin
endofstudi
chisquar
wilcoxon
ranksum
test
use
assess
baselin
group
differ
categor
continu
variabl
respect
fisher
exact
test
poisson
regress
use
compar
toxic
two
group
efficaci
outcom
assess
threemonth
period
januari
march
primari
analys
toxic
outcom
entir
studi
neg
binomi
regress
use
assess
effect
treatment
arm
rate
event
exposur
time
includ
model
subject
return
diari
neg
binomi
model
use
varianc
outcom
greater
predict
poisson
model
model
age
gender
strata
use
covari
fisher
exact
test
use
assess
differ
proport
subject
seroconvers
vs
measur
viral
pathogen
poisson
regress
use
compar
seroconvers
rate
origin
design
sampl
size
patient
per
group
would
allow
detect
differ
number
ari
day
power
twosid
level
signific
assum
coeffici
variat
accrual
bolster
account
assum
dropout
rate
two
hundr
ninetythre
subject
enrol
novemb
subject
random
activ
drug
placebo
figur
twelv
patient
complet
diari
decid
particip
studi
random
one
refus
complet
diari
one
addit
patient
complet
diari
incorrectli
subject
exclud
leav
analyz
subject
activ
treatment
group
placebo
arm
tabl
show
subject
characterist
group
signific
differ
group
characterist
one
hundr
twenti
subject
activ
treatment
group
subject
placebo
arm
complet
studi
reason
withdraw
similar
group
two
subject
activ
group
one
subject
placebo
group
withdrew
due
toxic
group
daili
diari
complet
return
mean
adher
prescrib
medic
patient
selfreport
complet
diari
group
ari
occur
subject
overal
threemonth
primari
studi
period
interest
overal
rate
ari
per
patient
day
averag
subject
experienc
ari
approxim
everi
day
signific
differ
two
priori
primari
endpoint
ari
day
recipi
vs
placebo
group
rate
vs
respect
p
sever
ari
day
recipi
vs
placebo
recipi
rate
vs
respect
p
two
priori
secondari
endpoint
antibiot
use
day
vs
placebo
p
jacksondefin
cold
day
vs
placebo
p
data
examin
proport
subject
experienc
ari
recipi
experienc
least
one
ari
day
vs
placebo
recipi
differ
ci
p
recipi
experienc
least
one
sever
ari
day
vs
placebo
recipi
differ
ci
p
intens
ari
defin
occurr
multipl
mild
symptom
one
moder
sever
symptom
experienc
recipi
vs
placebo
group
differ
ci
p
analysi
specif
moderatesever
symptom
sore
throat
cough
runni
nose
congest
sneez
earach
myalgia
fever
fatigu
headach
chill
short
breath
show
significantli
lower
rate
sore
throat
p
moderatesever
symptom
p
group
figur
subject
serum
specimen
avail
baselin
endofstudi
experienc
seroconvers
common
respiratori
viru
tabl
recipi
vs
placebo
group
tabl
p
seroconvers
viru
could
occur
also
determin
seroconvers
occur
subject
seroconvers
ratecold
season
vs
placebo
recipi
p
studi
design
allow
serolog
sampl
beforeaft
ari
episod
one
match
given
ari
event
specif
viral
etiolog
howev
subject
experienc
seroconvers
asymptomat
throughout
studi
period
ie
experienc
ari
day
four
group
one
placebo
group
suggest
asymptomat
convers
five
subject
seroconvers
vs
coronaviru
piv
type
suggest
influenza
rsv
hmpv
piv
type
like
symptomat
signific
differ
either
group
prev
postwbc
platelet
count
total
serum
igg
level
percent
cell
microglobulin
given
short
durat
studi
one
would
expect
progress
cll
mani
patient
differ
group
prepor
postintervent
measur
rai
stage
well
toler
toxic
evalu
number
patient
experienc
toxic
rate
time
subject
could
experi
event
overal
number
subject
rate
advers
event
ae
seriou
ae
differ
group
commonli
report
ae
group
number
subject
activ
group
vs
placebo
group
joint
pain
vs
insomnia
vs
hyperglycemia
vs
headach
vs
howev
differ
rate
sever
grade
higher
toxic
report
group
januari
subject
control
arm
compar
arm
experienc
least
one
grade
higher
toxic
p
howev
control
patient
experienc
greater
cumul
number
grade
toxic
vs
p
acut
respiratori
ill
ari
common
cll
ari
symptom
occur
day
januari
march
enrol
subject
significantli
reduc
ari
day
antibiot
use
though
trend
note
reduct
rate
moderatelysever
ari
signific
reduct
seen
rate
either
modsever
symptom
modsever
sore
throat
greater
proport
recipi
experienc
seroconvers
common
virus
vs
p
previou
studi
note
high
rate
respiratori
infect
cll
patient
nearli
prior
studi
examin
patient
cll
later
stage
requir
treatment
knowledg
first
studi
determin
incid
ari
untreat
earlystag
cll
patient
subject
studi
experienc
least
one
ari
ari
symptom
report
day
januari
st
march
st
rate
similar
previous
publish
data
healthi
communitydwel
older
adult
vast
major
day
symptom
mild
result
antibiot
use
averag
number
antibiot
use
day
group
mild
natur
ari
symptom
may
due
rel
mild
influenza
activ
http
wwwcdcgovfluweeklyfluactivityhtm
inde
subject
serolog
data
episod
influenza
seroconvers
confirm
tabl
limit
studi
symptom
serolog
use
identifi
ari
prospect
surveil
use
pcr
viral
cultur
would
prefer
beyond
scope
support
avail
studi
four
prior
random
control
studi
adult
popul
safe
reduc
ari
risk
first
studi
cll
subject
safeti
toler
evid
trial
differ
vs
placebo
recipi
howev
effect
ari
ill
day
antibiot
use
prioridefin
endpoint
lack
efficaci
reach
ari
endpoint
cll
patient
could
due
multipl
factor
accumul
data
mechan
indic
innat
immun
modul
act
tolllik
receptor
surfac
cell
activ
lead
increas
number
function
cell
within
innat
adapt
immun
system
howev
current
method
measur
bloodtissu
level
activ
compound
measur
bioassay
allow
correl
outcom
evid
drug
effect
possibl
pathway
suffici
influenc
dose
util
demonstr
clinic
benefit
cll
patient
tolllik
receptor
pathway
impair
cll
patient
howev
result
regard
seroconvers
suggest
otherwis
see
indic
studi
higher
dose
warrant
addit
worth
note
variabl
symptomdefin
measur
far
greater
seen
previou
studi
nonleukem
particip
may
contribut
failur
reach
signific
knowledg
first
studi
cll
patient
treat
immun
modul
agent
comprehens
evalu
seroconvers
vs
multipl
viral
pathogen
caus
ari
serolog
data
tabl
suggest
increas
antibodi
occur
frequent
recipi
reach
statist
signific
combin
viral
infect
rate
increas
viral
exposur
risk
recipi
seem
unlik
increas
risk
viral
infect
consist
clinic
data
show
trend
toward
lower
incid
moderatelysever
ari
recipi
seroconvers
data
much
consist
enhanc
immun
respons
result
therapi
sensit
detect
seroconvers
rest
document
rise
titer
cll
patient
gener
impair
antibodi
respons
thu
like
explan
demonstr
seroconvers
rate
differ
manifest
enhanc
virusspecif
antibodi
respons
hypothesi
evalu
group
other
summari
ari
common
complic
patient
untreat
cll
averag
one
day
everi
ten
ari
day
winter
respiratori
viru
season
welltoler
reduc
number
ari
day
sever
ari
day
two
priori
primari
endpoint
antibiot
use
therapi
howev
associ
trend
toward
reduc
rate
intens
ari
signific
reduct
percent
subject
report
moderatelysever
sore
throat
moderatesever
symptom
grade
toxic
signific
increas
rate
seroconvers
vs
respiratori
viral
pathogen
recipi
like
reflect
augment
antibodi
respons
futur
research
examin
whether
affect
antibodi
titer
immun
cll
patient
whether
higher
dose
might
effect
reduc
ari
incid
sever
consort
diagram
subject
enrol
studi
respiratori
ill
symptom
report
moderatesever
percent
subject
group
report
moderatesever
acut
respiratori
ill
symptom
worst
report
sever
janmar
shown
number
subject
experienc
seroconvers
rise
antibodi
titer
vs
nine
common
respiratori
virus
entir
studi
period
subject
serum
sampl
avail
baselin
endofstudi
thu
includ
analysi
total
given
proport
subject
group
experienc
seroconversioncold
season
sinc
individu
could
seroconvert
one
viru
rate
seroconversionscold
season
group
also
shown
